Recent Advances and Challenges of mTOR Inhibitors Use in the Treatment of Patients with Tuberous Sclerosis Complex
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Tuberous sclerosis complex (TSC) is a genetic condition characterized by the presence of benign, noninvasive, and tumor‐like lesions called hamartomas that can affect multiple organ systems and are responsible for the clinical features of the disease. In the majority of cases, TSC results from mutations in the TSC1 and TSC2 genes, leading to the overactivation of the mammalian target of rapamycin (mTOR) signalling pathway, which controls several cell functions, including cell growth, proliferation, and survival. The establishment of a connection between TSC and mTOR led to the clinical use of drugs known as mTOR inhibitors (like rapamycin, also known as sirolimus and everolimus), which are becoming an increasingly interesting tool in the management of TSC‐associated features, such as subependymal giant cell astrocytomas, renal angiomyolipomas, and also epilepsy. However, the intrinsic characteristics of these drugs and their systemic effects in such a heterogeneous condition pose many challenges in clinical practice, so that some questions remain unanswered. This article provides an overview of the pharmacological aspects of mTOR inhibitors about the clinical trials leading to their approval in TSC‐related conditions and exposes current challenges and future directions associated with this promising therapeutic line.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“molecularly, Tsc1 and Tsc2 mutations are known to result in overactive mTORC1 (mammalian target of rapamycin complex 1)”
From Behavioral phenotyping identifies autism-like repetitive stereotypies in a Tsc2 haploinsufficient rat model (2025) · cites this paper as [24]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Loewith, R., Jacinto, E., Wullschleger, S., Lorberg, A., Crespo, J. L., Bonenfant, D., Oppliger, W., Jenoe, P., & Hall, M. N. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00636-6 · Cited by 1,886 · cited 1×
“Two complexes (mTORC1 and mTORC2), with different composition, control mTOR actions [8, 14, 15] (Figure 1).”
BackgroundThe Tuberous Sclerosis Complex
Crino, P. B., Nathanson, K. L., & Henske, E. P. (2006) · New England Journal of Medicine · doi:10.1056/nejmra055323 · Cited by 1,793
Northrup, H., Krueger, D. A., Northrup, H., Krueger, D. A., Roberds, S., Smith, K., Sampson, J., Korf, B., Kwiatkowski, D. J., Mowat, D., et al. (2013) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2013.08.001 · Cited by 1,502
Brugarolas, J., Lei, K., Hurley, R. L., Manning, B. D., Reiling, J. H., Hafen, E., Witters, L. A., Ellisen, L. W., & Kaelin, W. G. (2004) · Genes & Development · doi:10.1101/gad.1256804 · Cited by 1,384
Efficacy and safety of sirolimus in lymphangioleiomyomatosis
McCormack, F. X., Inoue, Y., Moss, J., Singer, L. G., Strange, C., Nakata, K., Barker, A. F., Chapman, J. T., Brantly, M. L., Stocks, J. M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1100391 · Cited by 1,099
mTOR kinase structure, mechanism and regulation
Yang, H., Rudge, D. G., Koos, J. D., Vaidialingam, B., Yang, H. J., & Pavletich, N. P. (2013) · Nature · doi:10.1038/nature12122 · Cited by 1,075
The mTOR signalling cascade: paving new roads to cure neurological disease
Crino, P. B. (2016) · Nature Reviews Neurology · doi:10.1038/nrneurol.2016.81 · Cited by 368
mTOR signaling and its roles in normal and abnormal brain development
Takei, N., & Nawa, H. (2014) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2014.00028 · Cited by 317
Research works printed but not linked: 64
- 10.1016/S0140-6736(08)61279-9 · DOI · Paper page
- 10.2165/00148581-200810050-00004 · DOI
- 10.1111/j.1749-6632.1991.tb37754.x · DOI · Paper page
- 10.1017/s0012162206001058 · DOI
- 10.1159/000254569 · doi:10.1159/000254569
- 10.1016/j.cell.2012.03.017 · DOI · Paper page
- 10.1038/nrm3025 · DOI · Paper page
- 10.1016/B978-0-12-802733-2.00002-5 · DOI
- 10.1016/B978-0-12-802733-2.00001-3 · DOI
- 10.1093/jmcb/mjq038 · DOI · Paper page
- 10.4103/2319-4170.110365 · DOI · Paper page
- 10.2174/138920310791824093 · DOI · Paper page
- 10.1016/s0092-8674(03)00929-2 · DOI · Paper page
- 10.1593/neo.08586 · DOI · Paper page
- 10.1172/JCI200215650 · doi:10.1172/jci200215650
- 10.1101/gad.1212704 · DOI · Paper page
- 10.1016/j.ceb.2005.09.009 · DOI · Paper page
- 10.4161/auto.7.11.17652 · DOI
- 10.1513/pats.200909-104js · DOI
- 10.1073/pnas.1104361108 · DOI · Paper page
- 10.4161/cc.27355 · DOI
- 10.1165/rcmb.2015-0022oc · DOI
- 10.1517/14656566.6.3.479 · DOI
- 10.2174/156800908786733513 · DOI
- 10.1186/1756-8722-2-45 · DOI · Paper page
- 10.1126/science.1715094 · DOI · Paper page
- 10.1093/neuonc/nov152 · DOI · Paper page
- 10.1517/14656566.7.10.1347 · doi:10.1517/14656566.7.10.1347
- 10.1042/CS20150149 · DOI
- 10.1177/1756287215574457 · DOI
- 10.1517/13543784.2013.831404 · DOI
- 10.2174/1570159x11209040404 · DOI
- 10.1007/s40265-016-0552-9 · DOI
- 10.1053/j.seminoncol.2009.10.009 · doi:10.1053/j.seminoncol.2009.10.009
- 10.1586/17512433.2013.827397 · DOI
- 10.1002/ana.20784 · DOI · Paper page
- 10.1056/nejmoa063564 · DOI · Paper page
- 10.1056/nejmc072500 · DOI · Paper page
- 10.1158/1078-0432.ccr-11-0445 · DOI · Paper page
- 10.7326/0003-4819-146-9-200705010-00022 · DOI
- 10.1016/j.athoracsur.2008.07.062 · DOI
- 10.1016/j.healun.2008.05.012 · DOI
- 10.7326/0003-4819-154-12-201106210-00007 · DOI · Paper page
- 10.1016/j.transproceed.2009.06.227 · DOI
- 10.1002/pbc.22401 · DOI
- 10.2165/11634580-000000000-00000 · DOI · Paper page
- 10.1056/NEJMoa1001671 · DOI · Paper page
- 10.1016/s0140-6736(12)61134-9 · DOI · Paper page
- 10.1016/S1470-2045(14)70489-9 · DOI · Paper page
- 10.1016/j.ejpn.2013.03.002 · DOI
- 10.1016/j.jpeds.2013.12.053 · DOI
- 10.1002/ana.23960 · DOI · Paper page
- 10.1016/j.pediatrneurol.2014.10.028 · DOI
- 10.1016/s0140-6736(12)61767-x · DOI · Paper page
- 10.1093/ndt/gfv249 · DOI · Paper page
- 10.1007/s11523-011-0174-9 · DOI
- 10.1016/j.trre.2014.03.002 · DOI · Paper page
- 10.1139/y77-007 · DOI · Paper page
- 10.1212/WNL.0b013e3182815428 · DOI · Paper page
- Sasongko T. H., 2016, Rapamycin and rapalogs for tuberous sclerosis complex, The Cochrane Database of Systematic Reviews
- di NardoA.et al. Cell biology of TSC-deficiency in neurons. Personal communication presented at the International TSC Research Conference Lisbon 3-5 November 2016.
- 10.1007/82-2010-64 · doi:10.1007/82-2010-64
- 10.1016/j.canlet.2013.06.017 · DOI · Paper page
- 10.1186/s13023-014-0182-9 · DOI · Paper page
Cited by
Management of epilepsy associated with tuberous sclerosis complex: Updated clinical recommendations
Curatolo, P., Nabbout, R., Lagae, L., Aronica, E., Ferreira, J. C., Feucht, M., Hertzberg, C., Jansen, A. C., Jansen, F., Kotulska, K., et al. (2018) · European Journal of Paediatric Neurology · doi:10.1016/j.ejpn.2018.05.006 · Cited by 190
Low-dose rapamycin extends lifespan in a mouse model of mtDNA depletion syndrome
Siegmund, S. E., Yang, H., Sharma, R., Javors, M., Skinner, O., Mootha, V., Hirano, M., & Schon, E. A. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddx341 · Cited by 92
Therapeutic Use of mTOR Inhibitors in Renal Diseases: Advances, Drawbacks, and Challenges
Viana, S. D., Reis, F., & Alves, R. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/3693625 · Cited by 48
“Nevertheless, this molecule also exhibits immunosuppressant, cytostatic, antiangiogenic, and antiproliferative properties, expanding the clinical applications to transplantation and oncology fields [10].”
BackgroundSelf-citationRamme, A., Zachow, M., Habelt, B., Vojtechova, I., Petrasek, T., Waltereit, R., & Bernhardt, N. (2025) · Behavioral and Brain Functions · doi:10.1186/s12993-025-00284-z · Cited by 1
Metadata
- Authors
- Palavra, F., Robalo, C., & Reis, F.
- Venue
- Oxidative Medicine and Cellular Longevity
- Publisher
- Wiley
- Published
- 2017-01
- Volume
- 2017
- Issue
- 1
- ISSN
- 1942-0900
- 1942-0994
- Cited by
- 53
- References
- 8
- Language
- en
- Funders
- Fundação para a Ciência e a Tecnologia (Pest-C/SAU/UI3282/2013, UID/NEU/04539/2013)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Recent Advances and Challenges of mTOR Inhibitors Use in the Treatment of Patients with Tuberous Sclerosis Complex. https://app.cochat.ai/papers/10.1155/2017/9820181
- The paper
- Palavra, F., Robalo, C., & Reis, F. (2017). Recent Advances and Challenges of mTOR Inhibitors Use in the Treatment of Patients with Tuberous Sclerosis Complex. Oxidative Medicine and Cellular Longevity. https://doi.org/10.1155/2017/9820181
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.